Document is current
Any future updates will be listed below
-
Authors
Gul, Seref https://orcid.org/0000-0002-5613-1339
Akyel, Yasemin Kubra https://orcid.org/0000-0002-1734-8340
Gul, Zeynep Melis
Isin, Safak https://orcid.org/0000-0002-7429-5257
Ozcan, Onur https://orcid.org/0000-0003-2022-3554
Korkmaz, Tuba
Selvi, Saba https://orcid.org/0000-0002-6965-1384
Danis, Ibrahim
Ipek, Ozgecan Savlug
Aygenli, Fatih
Taskin, Ali Cihan
Akarlar, Büşra Aytül
Ozlu, Nurhan https://orcid.org/0000-0002-5157-8780
Ozturk, Nuri https://orcid.org/0000-0001-5206-4127
Ozturk, Narin
Ünal, Durişehvar Özer
Guzel, Mustafa
Turkay, Metin https://orcid.org/0000-0003-4769-6714
Okyar, Alper
Kavakli, Ibrahim Halil https://orcid.org/0000-0001-6624-3505
- License Information
-
More Information
Article History
Received: 3 July 2021
Accepted: 31 October 2022
First Online: 8 November 2022
Competing interests
: The M47 studied in this paper is awarded of the following patent: WO2021137771A1 (World Intellectual Property Organization, Patent Cooperation Treaty). S.G., M.T., and I.H.K. are inventors in these patent applications, while Koc University is the assignee. The title of the patent is “11-(4-chlorophenyl)−4-(2,3-dihydro-1h-indole-1-carbonyl)−3,11-dimethyl-5,10,dioxatricyclo[7.4.0.0,2,6,]trideca-1,3,6,8-tetraen-13-one and derivatives as destabilizer of cry1 for the treatment of circadian rhythm associated diseases and disorders”. The invention provided an anticancer molecule against cancers harboring p53 mutations. The other authors declare that they have no competing interests.
